Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPRA | P18433 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | NAMPT | P43490 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.32 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9631444 | 0.83 | MAPT (0.47) | PTPRASMN1; SMN2MAPTGAAOPRM1 | |
| SCHEMBL29163914 | 0.78 | TSHR (0.35) | EPHX2MEN1KMT2ARECQLMAPK1 | |
| SCHEMBL29163911 | 0.78 | TSHR (0.35) | EPHX2MEN1KMT2ARECQLMAPK1 | |
| Hydrochloric Acid SCHEMBL7278125 | 0.76 | TSHR (0.36) | EPHX2MAPTGAAMEN1KMT2A | |
| SCHEMBL2218168 | 0.75 | MAPT (0.43) | SMN1; SMN2EPHX2MAPTGAAHTT | |
| SCHEMBL8120909 | 0.75 | MAPT (0.43) | SMN1; SMN2EPHX2MAPTGAAHTT | |
| SCHEMBL2216604 | 0.75 | MAPT (0.43) | SMN1; SMN2EPHX2MAPTGAAHTT | |
| SCHEMBL1325536 | 0.75 | MAPT (0.43) | SMN1; SMN2EPHX2MAPTGAAHTT | |
| SCHEMBL3570843 | 0.75 | MAPT (0.43) | SMN1; SMN2EPHX2MAPTGAAHTT | |
| SCHEMBL29599645 | 0.75 | MAPT (0.43) | SMN1; SMN2EPHX2MAPTGAAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7314879-B2 | Melanocortin receptor agonists | ELI LILLY AND COMPANY (US) | 2008-01-01 | — | — | US | disclosed |
| US-7169777-B2 | Melanocortin receptor agonists | ELI LILLY AND COMPANY (US) | 2007-01-30 | — | — | US | disclosed |
| US-7157463-B2 | Substituted piperidines/piperazines as melanocortin receptor agonists | ELI LILLY AND COMPANY (US) | 2007-01-02 | — | — | US | disclosed |
| EP-1469851-B1 | MELANOCORTIN RECEPTOR AGONISTS | LILLY CO ELI (US) | 2006-10-11 | — | — | EP | disclosed |
| US-20050075344-A1 | Melanocortin receptor agonists | ELI LILLY AND COMPANY | 2005-04-07 | — | — | US | disclosed |
| EP-1469851-A1 | MELANOCORTIN RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2004-10-27 | — | — | EP | disclosed |
| US-20040116699-A1 | Melanocortin receptor agonists | ELI LILLY AND COMPANY | 2004-06-17 | — | — | US | disclosed |
| US-20040058936-A1 | Substituted piperidines/piperazines as melanocortin receptor agonists | ELI LILLY AND COMPANY | 2004-03-25 | — | — | US | disclosed |
| EP-1368339-A1 | SUBSTITUTED PIPERIDINES/PIPERAZINES AS MELANOCORTIN RECEPTOR AGONISTS | Eli Lilly & Company (US) | 2003-12-10 | — | — | EP | disclosed |
| EP-1358163-A1 | MELANOCORTIN RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2003-11-05 | — | — | EP | disclosed |
| WO-2003061660-A1 | MELANOCORTIN RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2003-07-31 | — | — | WO | disclosed |
| WO-2002059107-A1 | SUBSTITUTED PIPERIDINES/PIPERAZINES AS MELANOCORTIN RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2002-08-01 | — | — | WO | disclosed |
| WO-2002059095-A1 | MELANOCORTIN RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2002-08-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075344-A1 | Melanocortin receptor agonists | MC4R, MC1R, MC5R | PTPRA 2881/4885SMN1; SMN2 2185/4885EPHX2 2221/4885 |
| US-20040058936-A1 | Substituted piperidines/piperazines as melanocortin receptor agonists | MC1R, MC4R, MC5R | PTPRA 3772/4885SMN1; SMN2 2576/4885EPHX2 4130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.